Carragelose effective against SARS-CoV-2 in cell culture assays

Marinomed is now planning clinical tests using the same technology for an inhalation solution that could also work in the lungs

20-Jul-2020 - Marinomed Biotech AG announces that pre-clinical data show that Carragelose® has the potential to reduce the risk of an infection with SARS-CoV-2 and may also treat COVID-19. Data from Marinomed’s cell-culture study confirm that Carragelose® works in a dose-dependent manner to strongly reduce the ...

Marinomed receives funding to research SARS-CoV-2 therapy

29-Apr-2020 - Marinomed Biotech AG receives funding from the Austrian Research Promotion Agency (FFG) for the development of a SARS-CoV-2 therapy based on Carragelose®. The aim of the project is to clinically test an inhalation solution as an acute treatment for viral pneumonia caused by SARS-CoV-2 or other ...

Marinomed Granted Chinese Patent for Antiviral Polymer

21-Nov-2012 - Marinomed Biotechnologie GmbH announced that it has been granted Chinese Patent No. CN101678040, entitled ‘Antiviral polymer’, by the Chinese patent office. The patent covers the use of a specific polymer for the prevention and treatment of rhinovirus infections.Dr. Andreas Grassauer, CEO and ...

Marinomed wins STEP award in "Market/Customer" category and special award for strategic partnerships

24-Nov-2010 - Marinomed Biotechnologie GmbH announced that it has won the €10,000-endowed Step Award 2010 in the "Market/ Customer” category. Marinomed also received an award in the amount of €5,000 for its strategic cooperation with the company, Boehringer Ingelheim Pharma. The special strategic partnership ...

Marinomed Signs Collaboration with Boehringer Ingelheim for Anti-Viral Nasal Spray Against Common Cold

01-Jul-2010 - Marinomed Biotechnologie GmbH announced that it has signed a licensing agreement with Boehringer Ingelheim. The deal will aim to further extend marketing of Marinomed’s anti-viral nasal spray for the treatment of the Common Cold to all of Europe (except Austria and UK), Russia and CIS, South ...

Marinomed’s MAM-06.301 achieves preclinical proof of concept

28-May-2010 - Marinomed Biotechnologie GmbH announced that MAM-06.301 has achieved preclinical proof of concept for the treatment of allergy and allergic asthma. The study is published in BMC Immunology. The compound, also referred to as beta-escin, was identified through screening as a potential ...

Marinomed Granted European Patent for Anti-Viral Active Ingredient

A core component of Marinomed’s respiratory technology platform

15-Mar-2010 - Marinomed Biotechnologie GmbH announced that it has been granted the European Patent No.2101792, entitled ‘Use of Carrageenan for treating Rhinovirus infections’ by the European Patent Office. Along with the antiviral polymer patent granted in April 2009, this patent covers a core component of ...

Marinomed Signs Drug Discovery Collaboration with BIOALVO

24-Sep-2009 - Marinomed Biotechnologie GmbH announced the signing of a deal with the Portuguese company BIOALVO under which the two companies will collaborate to find drug candidates screened from BIOALVO’s PharmaBUG marine extract library. Financial terms were not disclosed. Under the terms of the deal ...

Marinomed Granted European Patent for Antiviral Polymer

04-May-2009 - Marinomed Biotechnologie GmbH announced that it has been granted European Patent No. 0001842546, entitled ‘Antiviral polymer’ by the European Patent Office. The patent covers the use of a specific polymer for the prophylactic and therapeutic treatment of rhinovirus infections. Dr Andreas ...

Bringing Mother Nature to Pharmacy

Marinomed wins Mercur 2008 innovation award

19-Dec-2008 - Marinomed Biotechnologie GmbH has been awarded the top prize in the Mercur 2008 innovation awards. This award to Marinomed honours the discovery of antiviral properties in a natural product and the rapid development of the discovery into a nasal spray for treating the common cold. The prestigious ...